Inventiva's (IVA) "Buy" Rating Reiterated at Canaccord Genuity Group

Key Points

• Inventiva's stock received a "buy" rating reiterated by Canaccord Genuity Group, with a target price of $20.00, suggesting a potential upside of 250.26%.
• The stock has a consensus rating of "Moderate Buy" and an average target price of $15.57, based on recommendations from six analysts.
• Inventiva is a clinical-stage biopharmaceutical company focusing on treatments for non-alcoholic steatohepatitis (NASH), with its lead product candidate, Lanifibranor, currently in Phase III clinical trials.

Inventiva (NASDAQ:IVA - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Canaccord Genuity Group in a report issued on Tuesday,Benzinga reports. They currently have a $20.00 target price on the stock. Canaccord Genuity Group's price objective indicates a potential upside of 250.26% from the company's previous close.

IVA has been the subject of a number of other reports. Guggenheim raised their price target on Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. HC Wainwright initiated coverage on Inventiva in a research note on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price target for the company. Finally, Piper Sandler initiated coverage on Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price target for the company. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.57.

Inventiva Trading Down 2.7%

NASDAQ:IVA opened at $5.71 on Tuesday. Inventiva has a 1-year low of $1.60 and a 1-year high of $6.50. The stock has a fifty day simple moving average of $4.67 and a 200 day simple moving average of $3.77.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.